All Outputs (5)

Neurosurgical application of olaparib from a thermo-responsive paste potentiates DNA damage to prolong survival in malignant glioma (2024)
Journal Article
Serra, R., Smith, S. J., Rowlinson, J., Gorelick, N., Moloney, C., McCrorie, P., Veal, G. J., Berry, P., Chalmers, A. J., Suk, I., Shakesheff, K. M., Alexander, C., Grundy, R. G., Brem, H., Tyler, B. M., & Rahman, R. (2024). Neurosurgical application of olaparib from a thermo-responsive paste potentiates DNA damage to prolong survival in malignant glioma. British Journal of Cancer, https://doi.org/10.1038/s41416-024-02878-2

Background: There is increased pan-cancer specific interest in repurposing the poly adenosine diphosphate-ribose polymerase-1 (PARP-1) inhibitor, olaparib, for newly diagnosed or recurrent isocitrate dehydrogenase wild type glioblastoma. We explore w... Read More about Neurosurgical application of olaparib from a thermo-responsive paste potentiates DNA damage to prolong survival in malignant glioma.

Tumour Heterogeneity and Disease Infiltration as Paradigms of Glioblastoma Treatment Resistance (2024)
Journal Article
Malhotra, P., & Rahman, R. (2024). Tumour Heterogeneity and Disease Infiltration as Paradigms of Glioblastoma Treatment Resistance. Onco, 4(4), 349-358. https://doi.org/10.3390/onco4040024

Isocitrate dehydrogenase wild-type glioblastoma, a Grade 4 malignant brain neoplasm, remains resistant to multimodal treatment, with a median survival of 16 months from diagnosis with no geographical bias. Despite increasing appreciation of intra-tum... Read More about Tumour Heterogeneity and Disease Infiltration as Paradigms of Glioblastoma Treatment Resistance.

Supramolecular hydrogels enable co-delivery of chemotherapeutics with synergistic efficacy against patient-derived glioblastoma cells and spheroids (2024)
Journal Article
Cavanagh, R. J., Baquain, S., Alexander, C., Scherman, O. A., & Rahman, R. (2024). Supramolecular hydrogels enable co-delivery of chemotherapeutics with synergistic efficacy against patient-derived glioblastoma cells and spheroids. RSC Advances, https://doi.org/10.1039/D4PM00177J

Drug combinations have been shown to be highly effective in many cancer therapies but the ratios of the individual drugs must be adjusted carefully and formulated appropriately to ensure synergistic action. Here we assessed combinations of doxorubici... Read More about Supramolecular hydrogels enable co-delivery of chemotherapeutics with synergistic efficacy against patient-derived glioblastoma cells and spheroids.

Radiogenomics as an Integrated Approach to Glioblastoma Precision Medicine (2024)
Journal Article
Sanchez, I., & Rahman, R. (2024). Radiogenomics as an Integrated Approach to Glioblastoma Precision Medicine. Current Oncology Reports, https://doi.org/10.1007/s11912-024-01580-z

Purpose of Review
Isocitrate dehydrogenase wild-type glioblastoma is the most aggressive primary brain tumour in adults. Its infiltrative nature and heterogeneity confer a dismal prognosis, despite multimodal treatment. Precision medicine is increa... Read More about Radiogenomics as an Integrated Approach to Glioblastoma Precision Medicine.

Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models (2024)
Journal Article
Cavanagh, R. J., Monteiro, P. F., Moloney, C., Travanut, A., Mehradnia, F., Taresco, V., …Alexander, C. (2024). Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models. Biomaterials Science, 12(7), 1822-1840. https://doi.org/10.1039/d3bm01931d

Combinations of the topoisomerase II inhibitor doxorubicin and the poly (ADP-ribose) polymerase inhibitor olaparib offer potential drug-drug synergy for the treatment of triple negative breast cancers (TNBC). In this study we performed in vitro scree... Read More about Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models.